Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (23684)	7/29/1998 1:39:00 PM
From: Mudcat	Respond to of 32384

Glad you finally see the light on this stock TexasDude.

To: Arthur Radley who wrote (23684)	7/29/1998 1:48:00 PM
From: Henry Niman	Respond to of 32384

They are only more important when the price is down :-). Actually, my comment was more directed at the content on the naysayer's posts (who actually imply LGND's price is down even when its up). In Biotechs, patience is frequently a virtue.

To: Arthur Radley who wrote (23684)	7/29/1998 1:50:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Speaking of fundamentals, I just read a post on a diabetes discussion group that indicated that clinical trials of 2nd and 3rd generation Rezulin compounds had been suspended. Is WLA developing 2nd and 3rd generation compounds of Rezulin, or are these trials of Sankyo? I'm trying to get a clarification if these suspended trials are actually Rezulin derivatives or competing compounds (like SBH's Avandia). Anyone have any info? Problems with TZDs should speed up rexinoid development by LLY or WLA, which of course would be a plus for LGND. Still haven't found any news, although WLA is down again today.